Prognostic significance of the Ki67 scoring categories in breast cancer subgroups

Clinical Breast Cancer

Volumn 14, Issue 5, 2014, Pages 323-329.e3

  Niikura, Naoki ^a   Masuda, Shinobu ^b   Kumaki, Nobue ^a   Xiaoyan, Tang ^b   Terada, Mizuho ^a   Terao, Mayako ^a   Iwamoto, Takayuki ^c   Oshitanai, Risa ^a   Morioka, Toru ^a   Tuda, Banri ^a   Okamura, Takuho ^a   Saito, Yuki ^a   Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a  

^a TOKAI UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

ER; Ki67; Prognostic marker; Proliferation; Subgroups

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LABELING INDEX; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84922653564     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.12.013     Document Type: Article

References (24)

1. Urruticoechea A. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23:7212-20.
2. de Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96:1504-13.
3. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesedealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736-47.
4. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103:1656-64.
5. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol 2011; 29:4273-8.
6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736-50.
7. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 yrial. J Clin Oncol 2009; 27:1168-76.
8. Zhang GC, Qian XK, Guo ZB, et al. Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients. Med Oncol 2012; 29:3222-31.
9. Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res 2011; 13:R122.
10. The World Health Organization. Histological Typing of Breast Tumors. Neoplasm 1983; 30:113-23.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-10.
12. Xiaoyan T, Kumaki N, Masuda S. Methods for evaluating the Ki-67 positive rate in breast cancer: comparison between Ki-67 labeling index determined by an imaging system and Ki-67 score assess by a pathologist. Jpn J Breast Cancer 2012; 27:321-6.
13. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17:323-34.
14. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26: 5569-75.
15. Tokiniwa H, Horiguchi J, Takata D, et al. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptorpositive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer 2012; 19:309-14.
16. Williams DJ, Cohen C, Darrow M, et al. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 2011; 19:431-6.
17. Millar EK, Graham PH, McNeil CM, et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 2011; 105:272-80.
18. Hida AI, Oshiro Y, Inoue H, et al. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells. Breast Cancer, published online Mar 31, 2013.
19. Honma N, Horii R, Iwase T, et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer, published online Mar 12, 2013.
20. Munzone E, Botteri E, Sciandivasci A, et al. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat 2012; 134:277-82.
21. Niikura N, Iwamoto T, Masuda S, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 2012; 103:1508-12.
22. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174-83.
23. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol 2011; 22:500-2.
24. Barton S, Zabaglo L, A'Hern R, et al. Assessment of the contribution of the IHC4+C score to decision-making in clinical practice in early breast cancer. Br J Cancer 2012; 106:1760-5.